FDA

Dear Research Advocate: Our elected representatives know they must make hard tax and entitlement reform decisions, and, for the sake of the nation, ensure those decisions foster economic growth and societal progress. Part of that equation is federal funding for medical research sufficient to capitalize on unprecedented scientific opportunity and tackle urgent threats like Alzheimer’€™s Disease. As I’€™ve highlighted before, a majority of Americans say they are willing to pay additional taxes ’€” $1 more per week (which amounts to approximately $4.4 billion annually) ’€” if they knew those dollars were funding medical research. The public is on our side with their wallets as well as their...
Dear Research Advocate: Our elected representatives know they must make hard tax and entitlement reform decisions, and, for the sake of the nation, ensure those decisions foster economic growth and societal progress. Part of that equation is federal funding for medical research sufficient to capitalize on unprecedented scientific opportunity and tackle urgent threats like Alzheimer’€™s Disease. As I’€™ve highlighted before, a majority of Americans say they are willing to pay additional taxes ’€” $1 more per week (which amounts to approximately $4.4 billion annually) ’€” if they knew those dollars were funding medical research. The public is on our side with their wallets as well as their...
by Mary Woolley, Research!America President and CEO. This entry was originally posted as a guest contribution to PhRMA’€™s Conversations forum. A shift in attitude among elected officials is necessary if this nation is to succeed in combating disease and stemming the rise of health care costs. Federal funding for the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and other agencies that conduct medical and health research has not kept pace with scientific opportunity, jeopardizing our ability to find cures for deadly disease and to maintain our global competitive edge. Medical research has not risen to the upper ranks of our nation’€™s priorities in the halls...
by Mary Woolley, Research!America President and CEO. This entry was originally posted as a guest contribution to PhRMA’€™s Conversations forum. A shift in attitude among elected officials is necessary if this nation is to succeed in combating disease and stemming the rise of health care costs. Federal funding for the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and other agencies that conduct medical and health research has not kept pace with scientific opportunity, jeopardizing our ability to find cures for deadly disease and to maintain our global competitive edge. Medical research has not risen to the upper ranks of our nation’€™s priorities in the halls...
The Food and Drug Administration announced Friday that it is proposing to establish a maximum level of arsenic acceptable in apple juice. The threshold, 10 parts per billion, is the same as the Environmental Protection Agency’€™s requirement for drinking water. The agency will accept public comments on the proposed action for 60 days. Nearly two years ago, reports from the TV show of Mehmet Oz, MD, and later Consumer Reports , raised alarms about the amount of arsenic appearing in apple juice. The FDA’€™s own subsequent investigation found that overall arsenic levels were generally below the 10 ppb threshold. Of those that were higher, the levels of inorganic arsenic ’€” identified as a...
The Food and Drug Administration announced Friday that it is proposing to establish a maximum level of arsenic acceptable in apple juice. The threshold, 10 parts per billion, is the same as the Environmental Protection Agency’€™s requirement for drinking water. The agency will accept public comments on the proposed action for 60 days. Nearly two years ago, reports from the TV show of Mehmet Oz, MD, and later Consumer Reports , raised alarms about the amount of arsenic appearing in apple juice. The FDA’€™s own subsequent investigation found that overall arsenic levels were generally below the 10 ppb threshold. Of those that were higher, the levels of inorganic arsenic ’€” identified as a...
Dear Research Advocate: Yesterday, I joined Diane Rehm and other guests on her nationally syndicated radio program to discuss how sequestration impacts “ordinary Americans.” I was struck by how deep and distressing the damage is, in so many sectors, including but not limited to our own. Yet somehow the pain is not acute enough to force action. What strikes me is how low our collective expectations have sunk when it comes to reinvigorating U.S. economic growth and prosperity. Our nation can do better; why don’€™t we maintain high expectations and hold our elected officials accountable for setting the policy stage to accomplish them? Policy makers should protect discretionary spending, make...
By Olivera J. Finn and Robert E. Schoen An excerpt of an op-ed by Olivera J. Finn, PhD a distinguished professor and chair of immunology at the University of Pittsburgh School of Medicine and Robert E. Schoen, MD, MPH professor of medicine and epidemiology at Pitt’s School of Medicine and Graduate School of Public Health published in the Pittsburgh Post-Gazette . Olivera J. Finn, PhD Robert E. Schoen, MD, MPH Every day, physicians and scientists see the hope and promise that medical research brings to patients and families. For nearly 70 years, research funded by the National Institutes of Health has increased understanding of the causes of disease, contributed to longer life expectancy and...
Dear Research Advocate: On Wednesday, the House Appropriations agriculture subcommittee approved the funding bill that includes the Food and Drug Administration. The bill allocates nearly $100 million above the post-sequester levels. Unfortunately, the baseline budgets in the House are so low that this increase is still lower than FY12 FDA funding. We must not fall into the trap of lowering our expectations and applauding an artificial victory. The true mark of success is funding that keeps up with need. We must keep working. As demonstrated particularly by the 18.6% cut targeted for the House LHHS appropriations FY14 budget, the pressure to shrink government by slashing discretionary...
Dear Research Advocate: I invite you to join me in speaking out during the Memorial Day congressional recess (May 27-31) as part of a social media campaign using the hashtag #curesnotcuts. Our goal is to continue to position research and innovation to improve health where it belongs: as a fundamental national priority that Americans can count on because their elected representatives rank it so highly. In our social media campaign, each day of the recess has a specific theme that can be customized with your information and patient/researcher stories. We have made it easy to get involved: click here to see sample social media messages, a list of selected congressional offices and their...

Pages

Sidebar Quote

Without continued support for health research, many of the most promising young scientists, their ideas and a myriad of potentially life-changing scientific breakthroughs will vanish into oblivion.
Paul Marinec, PhD; University of California San Francisco